Janssen-Cilag's Stelara approved in EU for psoriasis
This article was originally published in Scrip
Executive Summary
The European Commission has approved Janssen-Cilag's (Johnson & Johnson) novel human monoclonal antibody drug Stelara (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis in adults who have failed to respond to, are intolerant to, or have a contraindication to other systemic therapies including ciclosporin, methotrexate and psoralen plus ultraviolet light (PUVA).